# US 8,278,116 B2 · Detecting succinylacetone

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,116 B2
- Document ID: US8278116B2
- Status: Granted
- Kind: B2
- Application number: 13/092,584
- Filed: 2011-04-22
- Published: 2011-08-18
- Granted: 2012-10-02
- Earliest claimed: 2007-05-04
- Assignees: PerkinElmer Health Sciences, Inc.
- Inventors: Blas Cerda; Alex Cherkasskiy; Yijun Li
- Web page: https://patentgrep.com/patent/US8278116B2

## CPC

- G01N 33/64: involving ketones
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 2800/04: Endocrine or metabolic disorders
- G01N 2800/50: Determining the risk of developing a disease
- Y10T 436/147777: Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
- Y10T 436/200833: Carbonyl, ether, aldehyde or ketone containing
- Y10T 436/201666: Carboxylic acid
- Y10T 436/24: Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
- Y10T 436/2525: Stabilizing or preserving
- Y10T 436/25375: Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
- Y10T 436/255: including use of a solid sorbent, semipermeable membrane, or liquid extraction
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

This invention relates, inter alia, to detecting and/or measuring succinylacetone and one or more additional biological analytes using mass spectrometry.

## Claims

### Claim 1

A method for detecting succinylacetone, the method comprising:
contacting a sample with an extraction solution comprising a C1-3 linear or branched chain monoalcohol and a strong base;
derivatizing succinylacetone in the sample; and
evaluating the derivatized succinylacetone in the derivatized sample using tandem mass spectrometry.

### Claim 2

A method for detecting succinylacetone, the method comprising:
contacting a sample with an extraction solution comprising a C1-3 linear or branched chain monoalcohol and hydrazine;
derivatizing succinylacetone to 3-(5-methyl-1H-pyrazol-3-yl)proprionic acid (MPP) in the sample; and
evaluating MPP in the derivatized sample using tandem mass spectrometry.

### Claim 3 (depends on 2)

The method of claim 2, further comprising evaluating the sample for one or more additional analytes.

### Claim 4 (depends on 3)

The method of claim 3, wherein the one or more additional analytes are evaluated with MPP in the same sample injection.

### Claim 5 (depends on 2)

The method of claim 2, wherein the extraction solution comprises at least about 5% water.

### Claim 6 (depends on 2)

The method of claim 2, wherein the extraction solution comprises less than about 85% of the C1-3 linear or branched chain monoalcohol.

### Claim 7 (depends on 2)

The method of claim 2, wherein the succinylacetone is derivatized with hydrazine or derivatized hydrazine.

### Claim 8 (depends on 2)

The method of claim 2, wherein the sample is a dried blood sample.

### Claim 9 (depends on 2)

The method of claim 2, wherein the sample is from a newborn human.

### Claim 10 (depends on 2)

The method of claim 2, further comprising determining whether a subject, from whom the sample was derived, has, or is at risk of developing, hereditary tyrosinemia type I, based on the detection of succinylacetone in the sample.

### Claim 11 (depends on 10)

The method of claim 10, further comprising after determining that the subject has, or is at risk of developing, hereditary tyrosinemia type I, administering to the subject an inhibitor of 4-hydroxyphenylpyruvate dioxygenase.

### Claim 12 (depends on 2)

The method of claim 2, wherein a derivatized succinylacetone comprising at least one heavy atom isotope is included in the sample prior to mass spectroscopic analysis.

### Claim 13

A method for detecting a biologically active ketone, the method comprising:
contacting a sample with an extraction solution comprising a C1-3 linear or branched chain monoalcohol and a strong base;
derivatizing a biologically active ketone in the sample; and
evaluating the derivatized biologically active ketone in the derivatized sample using tandem mass spectrometry.

### Claim 14 (depends on 13)

The method of claim 13, wherein the biologically active ketone is succinylacetone.

### Claim 15 (depends on 13)

The method of claim 13, wherein the biologically active ketone is a steroid.

### Claim 16

A kit for detecting succinylacetone, the kit comprising:
derivatized succinylacetone comprising at least one heavy atom isotope;
an extraction solution comprising a C1-3 linear or branched chain monoalcohol and a strong base; and
instructions for how to detect the derivatized succinylacetone.

### Claim 17 (depends on 16)

The kit of claim 16, wherein the derivatized succinylacetone is 3-(5-methyl-1H-pyrazol-3-yl) propionic acid (MPP).

### Claim 18 (depends on 16)

The kit of claim 16, wherein the strong base is hydrazine.

### Claim 19 (depends on 18)

The kit of claim 18, wherein the hydrazine is hydrazine dihydrochloride.

### Claim 20 (depends on 18)

The kit of claim 18, wherein the hydrazine is in solution at a concentration of less than about 0.1%.

### Claim 21 (depends on 16)

The kit of claim 16, further comprising one or more internal standards, each internal standard comprising: (i) an amino acid, free carnitine, or an acylcarnitine and (ii) at least one heavy atom isotope.

### Claim 22 (depends on 16)

The kit of claim 16, further comprising at least one dried blood spot comprising a known amount of one or more of succinylacetone, an amino acid, free carnitine, or an acylcarnitine.

### Claim 23

A method for extraction, the method comprising:
contacting a sample with an extraction solution, the extraction solution comprising a C1-3 linear or branched chain monoalcohol and a strong base, wherein contacting the sample with the extraction solution yields an extract comprising (i) derivatized succinylacetone, (ii) one or more amino acids, (iii) free carnitine, (iv) one or more acylcarnitines or (v) a derivatized form of (ii), (iii), or (iv) from the sample, wherein the concentration of the derivatized succinylacetone if present in the extract reflects the concentration of succinylacetone in the sample, and wherein the concentrations of the one or more amino acids, free carnitine, one or more acylcarnitines, or derivatized forms thereof if present in the extract reflect their respective concentrations in the sample.

### Claim 24 (depends on 23)

The method of claim 23, further comprising after contacting the sample with the extraction solution, analyzing the sample using tandem mass spectrometry.

### Claim 25 (depends on 23)

The method of claim 23, wherein the contacting derivatizes at least one succinylacetone molecule to 3-(5-methyl-1H-pyrazol-3-yl) propionic acid (MPP).

### Claim 26 (depends on 23)

The method of claim 23, wherein the sample is a biological sample.

### Claim 27 (depends on 26)

The method of claim 26, wherein the biological sample is a dried blood sample.

### Claim 28 (depends on 23)

The method of claim 23, wherein the extraction solution further comprises water.

### Claim 29 (depends on 23)

The method of claim 23, wherein the extraction solution comprises between about 5% to about 30% water.

### Claim 30 (depends on 23)

The method of claim 23, wherein the strong base is hydrazine.

### Claim 31 (depends on 23)

The method of claim 23, wherein the strong base is a modified hydrazine.

### Claim 32 (depends on 23)

The method of claim 23, wherein the extraction solution further comprises an organic acid.

### Claim 33 (depends on 32)

The method of claim 32, wherein the organic acid is oxalic acid.

### Claim 34 (depends on 23)

The method of claim 23, wherein the extraction solution further comprises one or more internal standards.

### Claim 35 (depends on 23)

The method of claim 23, further comprising after contacting the sample with the extraction solution, evaporating the sample resulting in a first evaporated sample.

### Claim 36 (depends on 35)

The method of claim 35, further comprising after evaporating the sample, contacting the first evaporated sample with an alkyl alcohol solution comprising an alkyl alcohol and an acid.

### Claim 37 (depends on 36)

The method of claim 36, wherein the alkyl alcohol is n-butanol.

### Claim 38 (depends on 36)

The method of claim 36, wherein the acid is HC1.

### Claim 39 (depends on 36)

The method of claim 36, further comprising after contacting the sample with the alkyl alcohol solution, evaporating the solution resulting in a second evaporated sample.

### Claim 40 (depends on 39)

The method of claim 39, further comprising reconstituting the second evaporated sample.

### Claim 41 (depends on 40)

The method of claim 40, wherein reconstituting comprises contacting the second evaporated sample with a solvent comprising acetonitrile.
